ライフサイエンスコーパス: cryptogenic stroke

1 diagnostic evaluation in 20 to 40% of cases (cryptogenic stroke).

2 troke prevention strategies in patients with cryptogenic stroke.

3 tory comparative studies, and case series on cryptogenic stroke.

4 sure versus medical therapy in patients with cryptogenic stroke.

5 s essential to determine the pathogenesis in cryptogenic stroke.

6 (AF) can be a cause of previously diagnosed cryptogenic stroke.

7 hophysiology have prompted a reassessment of cryptogenic stroke.

8 cardiography in the diagnostic evaluation of cryptogenic stroke.

9 w-up for detecting atrial fibrillation after cryptogenic stroke.

10 tecting atrial fibrillation in patients with cryptogenic stroke.

11 may represent an opportunity for those with cryptogenic stroke.

12 n patients with pacemakers and patients with cryptogenic stroke.

13 ggests a causal relationship between PFO and cryptogenic stroke.

14 n attempt to quantitate PFO in patients with cryptogenic stroke.

15 vale may prevent a substantial proportion of cryptogenic strokes.

16 2 (32%) had cryptogenic events (incidence of cryptogenic stroke 0.36 per 1000 population per year, 95

17 When applied to patients with cryptogenic stroke, 17% are predicted to be large-vessel

18 Cryptogenic stroke accounts for 30% to 40% of ischemic s

19 Stroke of undetermined aetiology or 'cryptogenic' stroke accounts for 30-40% of ischaemic str

20 Of these, 265 patients experienced cryptogenic stroke and 365 experienced known stroke subt

21 We investigated whether patients with cryptogenic stroke and echocardiographic features repres

22 at can help identify potential mechanisms in cryptogenic stroke and patients who may be targeted for

23 potentiator of stroke risk in patients with cryptogenic stroke and PFO is a concomitant atrial septa

24 early 30,000 young patients each year have a cryptogenic stroke and PFO.

25 Cryptogenic Stroke and Underlying Atrial Fibrillation (C

26 There is persuasive evidence that most cryptogenic strokes are thromboembolic.

27 is increasingly accepted that many of these cryptogenic strokes arise from a distant embolism rather

28 Among patients who had had a recent cryptogenic stroke attributed to PFO with an associated

29 Among patients with PFO and cryptogenic stroke, closure reduced recurrent stroke and

30 or dependency at 6 months was similar after cryptogenic stroke compared with non-cardioembolic strok

31 atent foramen ovale (PFO) is associated with cryptogenic stroke (CS), although the pathogenicity of a

32 Detection of atrial fibrillation after cryptogenic stroke has therapeutic implications.

33 re several possible mechanisms implicated in cryptogenic stroke, including occult paroxysmal atrial f

34 of patent foramen ovale among patients with cryptogenic stroke is higher than that in the general po

35 n used for cardiac disorders, but its use in cryptogenic stroke is not well established.

36 e precise role of PFO in the pathogenesis of cryptogenic stroke is not yet established.

37 in the prevention of recurrent stroke after cryptogenic stroke is uncertain.

38 cal therapy versus medical therapy alone for cryptogenic stroke is uncertain.

39 t ischemic stroke in patients who have had a cryptogenic stroke is unknown.

40 In patients with stroke, especially cryptogenic stroke, large aortic plaques remain associat

41 In patients with cryptogenic stroke or TIA who had a patent foramen ovale

42 Among patients with a recent cryptogenic stroke or TIA who were 55 years of age or ol

43 18 and 60 years of age who presented with a cryptogenic stroke or transient ischemic attack (TIA) an

44 is suspected (as in patients presenting with cryptogenic stroke) or when an ECG diagnosis of unexplai

45 hing incidental PFOs from pathogenic ones in cryptogenic stroke patients and for identifying patients

46 Three-year monitoring by ICM in cryptogenic stroke patients demonstrated a significantly

47 mized study to report the detection of AF in cryptogenic stroke patients using continuous long-term m

48 The risk was highest among cryptogenic stroke patients, both for large plaques (HR,

49 rences in stroke prevention strategies among cryptogenic stroke patients.

50 pulation is around 25%, but it is doubled in cryptogenic stroke patients.

51 Of the cryptogenic strokes predicted to be cardioembolic, 27% w

52 The Patent foramen ovale In Cryptogenic Stroke Study (PICSS) evaluated transesophage

53 pirin as part of the Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS), based on the Warfarin-

54 The PFO in Cryptogenic Stroke Study was a 42-center study that eval

55 e more prevalent among patients experiencing cryptogenic stroke than among those with strokes of know

56 Among patients with a PFO who had had a cryptogenic stroke, the risk of subsequent ischemic stro

57 RATIONALE: Cryptogenic strokes, those of unknown cause, have been e

58 n the diagnostic evaluation of patients with cryptogenic stroke to identify potential aetiologies suc

59 The cause of cryptogenic stroke was predicted based on a model develo

60 involving patients with a PFO who had had a cryptogenic stroke, we randomly assigned patients, in a

61 Patients with prior cryptogenic stroke were randomized to control (n=220) or